Referring to the World Health Organization criteria, elderly patients with chronic hepatitis B are chronic hepatitis B patients aged ≥ 60 years. In general, the treatment of elderly patients can refer to the general treatment plan for patients with chronic hepatitis B. Age should not be a contraindication to antiviral therapy for chronic hepatitis B. However, the following issues should be noted in elderly patients: 1. The treatment of elderly patients should be a comprehensive assessment of the patient’s willingness to treat, the risk of treatment, and the benefit of treatment. In particular, patients treated with IFN a should be comprehensively evaluated for expected survival, liver function metabolism, tolerance to possible adverse effects, combined underlying diseases such as hypertension, diabetes, coronary artery disease, and possible improvement of liver function after treatment. 2. Patients should be closely monitored for treatment response and adverse reactions during and after treatment, and attention should also be paid to monitoring patients’ blood glucose, renal function, and the occurrence of hepatocellular carcinoma.